Selexis Announces Promotion of Dr. Pierre-Alain Girod to Chief Scientific Officer
GENEVA, SWITZERLAND, November 20, 2007
Selexis SA, a Swiss-based biotechnology company offering technologies and services to enable significantly improved drug discovery, development, and cGMP production, announced today the promotion of Dr. Pierre-Alain Girod to Chief Scientific Officer.
“I am very pleased to make this announcement” said Dr. Igor Fisch, CEO of Selexis, SA. “Pierre-Alain has held a key leadership position in our growing company and has played a major scientific role in the advancement of our core-technology based on Selexis proprietary Genetic Elements called SGE™. His contributions in the expansion of our SGE™ offering as well as the advancement of our SURE Cell Line Development Process has been outstanding and with our scientific organization likely to double again in 2008, I couldn’t ask for anyone better to lead this team. Pierre-Alain will be fully responsible for all R&D operations at Selexis SA in Geneva and will also be in charge of coordinating our efforts in maintaining a strong link with the University of Lausanne.
Pierre-Alain obtained his PhD in Biochemistry from the University of Lausanne and completed his scientific training as a post-doctoral fellow at the University of Wisconsin-Madison, USA. Prior to joining Selexis, he worked at the Department of Biology at the University of Lausanne in the field of targeted protein degradation. He has co-authored a number of scientific papers and patent applications.
About Selexis:
Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services that enables significant improvements in the time, effort and costs required to develop and maintain high performance mammalian cell lines for use in the expression of pharmaceutically relevant proteins (i.e. targets, MABs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of enabling genetic elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements™ using the SURE Cell Line DevelopmentSM process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.
Selexis Genetic Elements™ and SURE Cell Line Development SM are trademarks of Selexis SA.
MORE INFORMATION:
EUROPE
Rachel Flaction
41 (0)22 308 93 60
infoATselexis.com
UNITED STATES
Andrew F. Sandford
(617) 595-5769
andrew.sanfordATselexis.com